Purine derivatives as A3 and A1 adenosine receptor agonists

US7825126B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Kenneth A. Jacobson · Silver Spring, US
• Bhalchandra V. Joshi · Madison, US
• Susanna Tchilibon · Jerusalem, IL

Key dates

• Filing date: Sep 2, 2005
• Grant date: Nov 2, 2010
• Expiry date: Sep 7, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are (N)-methanocarba adenine nucleosides of the formula:as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. The invention also provides compounds that are agonists of both A1 and A3 adenosine receptors for use in cardioprotection.